- Home
- CSTL vs ADV Comparison
CSTL vs ADV Comparison
Compare CSTL & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- ADV
- Stock Information
- Founded
- CSTL 2007
- ADV 1987
- Country
- CSTL United States
- ADV United States
- Employees
- CSTL N/A
- ADV N/A
- Industry
- CSTL Medical Specialities
- ADV Business Services
- Sector
- CSTL Health Care
- ADV Consumer Discretionary
- Exchange
- CSTL Nasdaq
- ADV Nasdaq
- Market Cap
- CSTL 697.9M
- ADV 586.7M
- IPO Year
- CSTL 2019
- ADV N/A
- Fundamental
- Price
- CSTL $22.75
- ADV $1.48
- Analyst Decision
- CSTL Strong Buy
- ADV Strong Buy
- Analyst Count
- CSTL 6
- ADV 1
- Target Price
- CSTL $37.67
- ADV $2.50
- AVG Volume (30 Days)
- CSTL 348.6K
- ADV 725.1K
- Earning Date
- CSTL 11-03-2025
- ADV 11-06-2025
- Dividend Yield
- CSTL N/A
- ADV N/A
- EPS Growth
- CSTL N/A
- ADV N/A
- EPS
- CSTL N/A
- ADV N/A
- Revenue
- CSTL $346,269,000.00
- ADV $3,527,054,000.00
- Revenue This Year
- CSTL N/A
- ADV N/A
- Revenue Next Year
- CSTL N/A
- ADV N/A
- P/E Ratio
- CSTL N/A
- ADV N/A
- Revenue Growth
- CSTL 20.40
- ADV N/A
- 52 Week Low
- CSTL $14.59
- ADV $1.04
- 52 Week High
- CSTL $35.84
- ADV $4.04
- Technical
- Relative Strength Index (RSI)
- CSTL 52.78
- ADV 35.21
- Support Level
- CSTL $22.28
- ADV $1.44
- Resistance Level
- CSTL $23.71
- ADV $1.56
- Average True Range (ATR)
- CSTL 1.05
- ADV 0.07
- MACD
- CSTL -0.12
- ADV -0.03
- Stochastic Oscillator
- CSTL 35.90
- ADV 7.00
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.